human-on-a-chip

Hesperos, Inc is proud to announce Dr. Virginia Smith’s recent publication in Frontiers in Cell and Developmental Biology which validates the Human-on-a-Chip method to model the rare autoimmune disease, Myasthenia Gravis. Read the full press release below: … Read More

Using Human-on-a-Chip technology to reduce animal testing in drug discovery

Senior Editor with Pharma Manufacturing interviews Hesperos executives Michael Shuler and Nathan Post on the rise of Human-on-a-Chip (HoaC) systems and how they are replacing the need for animal testing in drug discovery.

fellow

Dr. James J. Hickman elected as Fellow of the National Acadamy of Inventors Hesperos is excited to announce that Chief Scientist, Dr. James J. Hickman, has been elected fellow of the National Academy of Inventors (NAI).  … Read More

human-on-a-chip

Presentation Highlights

This is a company overview presentation given by Dr. James Hickman at this years Florida Simulation Summit 2020 in October.  Learn more about the technology and exciting path ahead. Key highlights from the presentation include:

  • A brief history of Hesperos
  • How the Human-on-a-Chip technology works and the current state of the technology
  • Key applications and path forward


Human-on-a-Chip®

Functional in vitro models that accurately predict how new drug candidates will impact the human body – something that has previously required animal testing or human clinical trials to determine.

What’s on each Chip?

Systemic toxicology models with interlinked organs, including: heart, liver, lung, brain, skin, muscle, GI tract, kidney, pancreas, endocrine, bone marrow and the neuromuscular junction in a serum free, recirculating medium utilizing a pumpless platform.

hesperos

The Tech Tribune, the journalistic arm of Crunchbase, recently selected Hesperos as one of the top 10 technology startups in Orlando. We are proud to be listed among the best companies in the City Beautiful. Award … Read More

ALS

Unraveling the pathologic role of skeletal muscle in ALS A key challenge in developing effective therapies for amyotrophic lateral sclerosis has been a poor understanding of the disease pathology. To address this issue, a team of … Read More